Media ReleasesINOVIQ

View All INOVIQ News

INOVIQ and Promega sign Global EXO-NET Agreement

INOVIQ Ltd (ASX:IIQ) (INOVIQ) and Promega Corporation (Promega) are partnering to unlock the commercial potential of exosomes for research, diagnostic and therapeutic applications. This agreement will offer Promega customers world-class exosome solutions for manual, automated and high-throughput exosome isolation and nucleic acid extraction.

Unlocking the commercial potential of exosomes

The strategic Supply and Distribution Agreement will provide researchers with world-class exosome research solutions to enable exosome biomarker discovery and diagnostics development. This agreement will leverage INOVIQ’s EXO-NET® pan-exosome capture tool and Promega expertise in nucleic acid purification systems.

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?